The three-month PDUFA extension is a clear negative for a pre-revenue biotech with a binary catalyst — traders should expect selling pressure as the approval timeline lengthens and uncertainty around the refined indication increases. Monitor for any FDA advisory committee updates or additional data disclosures in the coming months, but the risk/reward is skewed negatively until the new November 22, 2026 decision date.
Price Chart
Executive Summary
Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Deramiocel BLA from August 22, 2026 to November 22, 2026, following a major amendment submission that included 24-month open-label extension data from the Phase 3 HOPE-3 study. The three-month delay is a negative catalyst for a pre-revenue biotech with a binary approval event, as it pushes the potential decision further out and introduces uncertainty around the refined proposed indication for upper limb function.
Key Facts
- FDA extended PDUFA target action date for Deramiocel BLA from August 22, 2026 to November 22, 2026.
- The extension is due to a major amendment submission including 24-month open-label extension data from the Phase 3 HOPE-3 study.
- The amendment requests FDA review of data supporting a refined proposed indication focused on upper limb function.
- Deramiocel holds Orphan Drug, RMAT, and Rare Pediatric Disease designations in the U.S.
Financial Impact
No financial figures provided in the filing; the delay pushes a binary approval event for a pre-revenue company by three months, extending the period of no product revenue.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on the November 22, 2026 PDUFA date, particularly given the refined indication request adds review complexity.
- The company has no approved products and no disclosed revenue, making it entirely dependent on Deramiocel approval for value realization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-100071 |
| Document: 0001104659-26-100071-index.html | 0001104659-26-100071 |
| Document: 0001104659-26-100071.txt | 0001104659-26-100071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G/A | $7.27 $6.13 | ▲ +15.68% | ▲ +14.67% | $5.91 (+18.71%) |
Aug 24, 2026 9w ago | 8-K | $6.80 $9.91 | ▼ −45.74% | ▼ −45.27% | $5.91 (+13.09%) |
Aug 21, 2026 9w ago | Institutional Cluster | $6.29 $9.59 | ▲ +52.46% | ▲ +51.99% | $5.91 (−6.04%) |
Jul 30, 2026 12w ago | Press Release | $4.19 $4.18 | ▲ +0.24% | ▲ +3.86% | $5.91 (−41.05%) |
Jul 14, 2026 14w ago | 8-K | $20.35 $18.91 | ▼ −7.08% | ▼ −6.10% | $5.91 (−70.96%) |
Jun 29, 2026 17w ago | Insider Cluster | $24.08 $22.43 | ▼ −6.85% | ▼ −7.46% | $5.91 (−75.46%) |
Jun 26, 2026 17w ago | 8-K | $23.80 $22.43 | ▼ −5.76% | ▼ −7.14% | $5.91 (−75.17%) |
Jun 24, 2026 17w ago | Insider Cluster | $30.40 $23.07 | ▼ −24.11% | ▼ −25.67% | $5.91 (−80.56%) |
Jun 1, 2026 21w ago | Court Ruling | $27.34 $26.01 | ▼ −4.86% | ▼ −1.90% | $5.91 (−78.38%) |
May 12, 2026 23w ago | Press Release | $30.33 $26.92 | ▼ −11.24% | ▼ −10.09% | $5.91 (−80.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers